#immuno-oncology (IO) market

[marketreports-blog]

According to recent study by nova one advisor, the global immuno-oncology (IO) market size was estimated at USD 43.73 billion in 2023 and is projected to hit around USD 284.29 billion by 2033, growing at a CAGR of 23.12% during the forecast period from 2024 to 2033.

[healthcaretechnologynews]

Is Merck’s Keytruda ahead of BMS Opdivo?

Both Keytruda and Opdivo are highly effective and commercially successful immunotherapies, yet Keytruda is at the forefront.

In newly diagnosed lung cancer, a commercial market opportunity that could reach $8 billion in sales annually, Merck’s Keytruda works and Bristol’s Opdivo does not.

With many failures in last 2-3 years for Nivolumab as monotherapy or as combination therapy, caused a fall flat, whereas consecutive accelerated approvals in past one year for Keytruda added to its market share and success.

Write to us at enquire@grgonline.com Learn how GRG Health is helping clients gather more in-depth market-level information on such topics.

We really don’t always get to see a head-on confrontation like the Merck’s Keytruda (pembrolizumab) and BMS Opdivo (nivolumab). These two have always been so much hyped immunotherapies along with other PD-1/L1 inhibitors.

But these two used to steal the show many a times in most of the international major conferences. Even though Opdivo has been approved earlier than Keytruda, yet, we feel that Keytruda was a better player. Both drugs are highly effective and commercially successful immunotherapies. Both are even effective in treating patients with lung cancer that no longer responds to prior therapies.

However, in newly diagnosed lung cancer, a commercial market opportunity that could reach $8 billion in sales annually, Merck’s Keytruda works and Bristol’s Opdivo does not. Keytruda, first approved for advanced melanoma in 2014, is Merck’s most important growth driver. It has overtaken Bristol’s Opdivo as the industry’s immuno-oncology leader with sales expected to top $10 billion this year and $20 billion in 2024, according to IBES data. Kidney cancer is the latest proving ground for IO in combination with other drugs.

While treatments like Keytruda (pembrolizumab) and Opdivo (nivolumab) have proved startlingly effective for a minority of patients — depending on the tumor type — most don’t experience a significant benefit. In response, biopharma companies have leaned on combinations, but only with modest success.

Bristol-Myers’ combo of Opdivo and Yervoy has been one of those successes, with approvals in metastatic melanoma, certain types of colorectal cancer and, most recently, advanced renal cell carcinoma. The pairing has also underpinned a good part of Bristol-Myers’ commercial success in immuno-oncology. As Keytruda has become the immunotherapy of choice in lung cancer, more of Opdivo’s growth has come in melanoma and renal cell carcinoma, according to Bristol-Myers’ executives.

However, the combination is also hampered by Yervoy’s side-effect profile, which includes severe and fatal immune-related adverse reactions like enterocolitis and neuropathy. With many failures in last 2-3 years for Nivolumab as monotherapy or as combination therapy, might be due to the kind of patient segments they recruited in the respective trials, caused a fall flat. On the contrary, consecutive accelerated approvals in past one year for Keytruda added-in Merck’s Kitty have made it a better player than Opdivo.

Visit our website now: https://www.grgonline.com/

[siva621]

Immuno Oncology Market: Empowering the Body to Fight Cancer

Introduction:

The field of cancer treatment has witnessed groundbreaking advancements over the years. Among these, Immuno Oncology (IO) Market has emerged as a revolutionary approach to combat cancer. This article delves into the realm of Immuno Oncology, exploring its mechanisms, current market players, trends, growth potential, challenges, regulatory landscape, and future prospects.

Understanding Immuno Oncology:

What is Immuno Oncology?

Immuno Oncology, also known as immunotherapy, is a specialized branch of cancer treatment that harnesses the body's immune system to recognize and attack cancer cells. Unlike traditional treatments like chemotherapy and radiation, IO stimulates the patient's immune response, helping it identify and eliminate cancer cells more effectively.

How does Immuno Oncology work?

IO treatments utilize various techniques to bolster the immune system. One of the key approaches involves using checkpoint inhibitors, which inhibit specific proteins that restrain the immune system, thereby allowing it to target cancer cells more efficiently.

The role of the immune system in cancer treatment:

The immune system plays a vital role in recognizing abnormal cells, including cancerous ones. However, cancer cells can develop strategies to evade the immune system. IO works to reverse this evasion, enabling the immune system to recognize and destroy cancer cells.

Key Players in the Immuno Oncology Market:

Pharmaceutical Companies:

Leading pharmaceutical companies have invested significantly in IO research and development. They are actively engaged in clinical trials and launching innovative IO therapies.

Biotechnology Firms:

Biotech companies are at the forefront of developing novel IO treatments. Their agility and focus on cutting-edge research have led to several promising advancements.

Research Institutions:

Academic and research institutions also play a crucial role in IO research. They contribute valuable insights and collaborate with industry players to drive progress.

Current Trends and Advancements:

Checkpoint Inhibitors:

Checkpoint inhibitors have revolutionized cancer treatment. They target specific proteins like PD-1 and CTLA-4, enhancing the immune system's ability to attack cancer cells.

CAR-T Cell Therapy:

CAR-T cell therapy involves modifying a patient's T-cells to express chimeric antigen receptors (CARs), enabling them to recognize and destroy cancer cells more effectively.

Cancer Vaccines:

Cancer vaccines are designed to stimulate the immune system to recognize and remember cancer cells, aiding in their elimination.

Adoptive Cell Transfer:

Adoptive cell transfer involves extracting, modifying, and reinfusing a patient's T-cells to boost their cancer-fighting capabilities.

Market Size and Growth Potential:

Global Immuno Oncology Market Size:

The IO market has experienced rapid growth in recent years, and it is projected to continue expanding at a substantial rate.

Factors driving market growth:

Increasing cancer prevalence, rising demand for effective and targeted therapies, and supportive government initiatives are fueling the growth of the IO market.

Future projections:

The IO market is poised for further growth, with ongoing research and development paving the way for groundbreaking treatments.

Challenges and Opportunities:

Managing Side Effects:

While IO treatments offer promising results, they can also cause immune-related side effects that need careful management.

Patient Access and Affordability:

Ensuring broad patient access to IO therapies and addressing cost concerns remain critical challenges.

Emerging Markets:

IO presents significant opportunities in emerging markets, where there is a rising demand for advanced cancer treatments.

Regulatory Landscape:

FDA Approval Process:

IO therapies undergo rigorous evaluation by regulatory authorities like the FDA to ensure safety and efficacy before approval.

Compliance and Safety:

Continuous monitoring of IO treatments is crucial to identify and address potential safety concerns.

International Regulations:

The IO market is subject to varying regulations across different countries, necessitating compliance with diverse standards.

Collaborations and Partnerships:

Industry-Academia Collaborations:

Collaborations between pharmaceutical companies and academic institutions foster innovation and knowledge exchange.

Cross-Industry Partnerships:

Partnerships between different industries can lead to innovative IO solutions and improved patient outcomes.

Future Outlook:

Innovations on the horizon:

Ongoing research holds the promise of introducing novel IO therapies with even higher efficacy.

Potential breakthroughs:

Combination therapies, personalized medicine, and targeting rare cancers are some areas that hold potential for significant breakthroughs.

Conclusion:

The Immuno Oncology market represents a transformative era in cancer treatment, where the body's own defense mechanisms are harnessed to fight the disease. With continuous advancements, collaborations, and regulatory support, the IO market is poised to offer new hope to cancer patients worldwide.

For more insights on the immuno-oncology market forecast, download a free report sample

[impossibledeanmakerwombat]

Biosimulation Market Current and Future Trends, Leading Players, Industry Segments and Regional Forecast to 2023 to 2032 | Says FMI

The Global Biosimulation Market according to a recent market study by Future Market Insights, was valued at US$ 2.6 billion in 2021 and is predicted to grow to US$ 20.9 billion by 2032. According to the report’s conclusions, biosimulation software will continue to be crucial for the market because it will account for the majority of sales. Software biosimulation will give the trials better and more effective findings, and there are many different types of software accessible for different types of research and application. From 2015 through 2021, the software segment’s revenue increased at a CAGR of 14.3%.

Revenue through Drug Development to Continue being growth Axis For Biosimulation Market

Pharmaceutical companies use biosimulation for drug development.  During a drug, development process biosimulation helps to identify the possible effects that the drug can have on a patient. The market through the drug development segment recorded a CAGR of 16.3% during 2015-2021.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16031

Biosimulation Market: Competition Insights

The key companies operating in the biosimulation market include Certara, Dassault Systemes, Advanced Chemistry Development, Simulation Plus Inc., Schrodinger, Inc., Chemical Computing Group, Physiomics Plc, Rosa & Co. LLC, BioSimulation Consulting Inc., Genedata AG, Instem Group of Companies, PPD, Inc., Insilico Biotechnology AG,  Rhenovia Pharma, LeadInvent Technologies, Nuventra Pharma, and In Silico  Biosciences.

Some of the recent developments by key providers of biosimulation are as follows:

In June 2022, Certara announced its new version of Biosimulation software for the progress of Novel Biologics. The new version includes Immunogenicity (IG), Immuno-Oncology (IO), and Vaccine simulators to understand and predict how drugs work and point out the key questions in the development of novel biologic therapies.

In June 2022, Genedata AG announced that Syros Pharmaceuticals has chosen Genedata AG’s Genedata Profiler as its data integration and investigative platform to accelerate its translational research strategy.

In March 2022, Advanced Chemistry labs announced that Pharmaron Inc. has chosen its NMR processing and interpretation software.

In March 2022, Simulation Plus, Inc. released its Membrane Plus 3.0 software. The new software includes improved data handling and simulation performance for in vitro-in vivo for extrapolation (IVIVE) for permeability, skin penetration, and release assay systems.

In February 2022, the US Food and Drug Administration (FDA) approved the license for Certara’s Immunogenicity (IG) stimulator to research and assess immunogenicity in protein-based remedies.

In February 2022, Physiomics Plc updated a new agreement with ValiRx plc. According to the new agreement, ValiRx will be able to use Physiomics Plc’s latest version of its Virtual Tumour technology. Physiomics Plc will also help ValiRx in modeling the use of VAL201 peptide in endometriosis (VAL301) and Coronavirus (BC201).

Limited time Offer, Get Customization @  https://www.futuremarketinsights.com/customization-available/rep-gb-16031

More Insights Available

Future Market Insights, in its new offering, presents an unbiased analysis of the Biosimulation Market, presenting historical market data (2017-2021) and forecast statistics for the period of 2022-2032.

The study reveals essential insights by Product Type (Services (In-house services, Contract services), Software), by Deployment mode (Drug Development, Drug Discovery, Other Applications), by End-use (Pharmaceutical & Biotechnology Companies, CROs, Regulatory Authorities, Academic Research Institutions), across five regions (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa).

Key Segments Covered in Biosimulation Industry Survey

Biosimulation Market by Product Type:

Services

In-house services

Contract services

Software

Biosimulation Market by Deployment Mode:

Drug Development

Drug Discovery

Other Applications

Biosimulation Market by End-use:

Pharmaceutical &Biotechnology Companies

CROs

Regulatory Authorities

Academic Research Instituitons

Full Report @ https://www.futuremarketinsights.com/reports/biosimulation-market

[industry365]

Immuno Oncology (IO) Market Is Expected To Reach New Growth Revenues During 2021-2028

The report “Global Immuno oncology (io) market Growth 2021-2028” from PMR Market Research includes data and information about market structure and size. The purpose of this research is to give market knowledge and strategic insights to assist in decision making, making informed investment decisions, and identifying potential growth opportunities.

The research report adopts primary and secondary research approaches, resulting in a precise and accurate insight into the Terminal Sterilization Services industry. To examine the segments and provide a fair assessment of their influence on the worldwide market, analysts utilized a top-down and bottom-up strategy. The study begins with a market overview, which includes a brief description of the industry's current state as well as the major segments. It also lists the leading players in the global market.

Download FREE Sample Copy  : https://www.polarismarketresearch.com/industry-analysis/immuno-oncology-io-market/request-for-sample

A Porter's five forces analysis and SWOT analysis are included in the research study on the global Immuno oncology (io) market, which empower to determine the market's accurate trajectory. Such effective market analysis tools helps to identify market’s major drivers, restraints, risks, and market opportunities. In addition to this, the research report also features statistics for global market as well as different regional markets.

Market Segmentation

The report features in-depth segmentation and sub-segmentation of the target market. The executive summary of the Immuno oncology (io) market research provides a quick overview of the market. It discusses the key sectors and companies projected to shape the market in the coming years. The executive summary provides a non-biased view of the market. It describes how the market's demand and supply will be affected by shifting demographics. It goes over the regulatory adjustments that are expected to change people's buying behavior.

COVID-19 Pandemic Impact Analysis

This Immuno oncology (io) market study discusses the impact of the COVID-19 pandemic on macro and micro aspects of business, hurdles encountered by each sector, and continuous efforts to turn this crisis into an opportunity. The research report also discusses government policies for recovering the economy in detail, in order to assist businesses in expanding or entering new markets, as well as introducing new products and services.

Exclusive Discount Offer on this Research Report : https://www.polarismarketresearch.com/industry-analysis/immuno-oncology-io-market/request-for-discount-pricing

Competitive Analysis

This section of the research study focuses on the market's leading players and competitive landscape. The Immuno oncology (io) market study provides a list of strategic efforts undertaken by companies in recent years, as well as those anticipated in the near future. The financial prospects of these companies, their research and development activities, and their expansion plans for the near future have all been noted by researchers. The global market research report is a serious endeavor to provide interested readers with a thorough view of the market.

Market participants such as Bristol Myers Squibb,Merck,AstraZeneca,Roche,Pfizer,Incyte

Key Reason to buy this Immuno oncology (io) market Research Report

It provides analytical data along with strategic planning approaches to help businesses make informed decisions.

The market's dynamics, such as drivers, restraints, trends, and opportunities, are examined by researchers.

It provides a wealth of information on current events that will have an impact on the market's overall performance.

It includes regional analysis of the global market as well as corporate profiles of various stakeholders.

[newsupdate-1]

Immuno Oncology Market Latest Trends, Growth Rate, Drivers And Regional Forecast

The global immuno-oncology market size is expected to reach USD 38.89 billion by 2025 according to a new study by Polaris Market Research. The report “Immuno Oncology (I-O) Market Size, Trends, Industry Analysis By Treatment Approaches (Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, and Cytokines); By Novel Targets (IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, and A2AR antagonist/CD73i); By Tumor Types; By Region: Market Size & Forecast, 2020 – 2026” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Immuno-oncology, also called as cancer immunotherapy is a biologic treatment, which enhances the body’s natural defenses to stop the growth of cancer. This therapy uses constituents made by the body or in a research laboratory to improve or reestablish the immune system function.

Get Sample copy of this report: https://www.polarismarketresearch.com/industry-analysis/immuno-oncology-io-market/request-for-sample

Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. Currently, world is at the forefront of this science with several compounds in development that are being investigated for use in a variety of cancers, as well as an approved immuno-oncology medicine that continues to be studied for new uses. The more precise targeting of patients for selected therapies is another important area of focus in oncology. Clinical biomarkers and pharmacogenomic studies are increasingly used to identify groups and sub-groups of patients most likely to benefit from an investigational agent in order to maximize its potential benefits.

The global immuno-oncology market is driven by the factors such as rising occurrence of different forms of cancer, technological advancements in the field of immune oncology for cancer treatment, and rising awareness concerning the benefits of ablation procedures over conventional treatment procedures. Moreover, rising number of ablation centers, surgical centers, and hospitals are driving the growth of tumor ablation market globally. Additionally, the developments in oncology treatments, leading to the increased development of pioneering products are also advancing towards significant growth of the global Immune Oncology market.

The increasing trend was also seen in the research in the novel agents and increase in the number of clinical trials in combinations as well as monotherapy. The most notable new agents in Immuno-Oncology are IDO’s, LAG-3, TIGIT, TIM-3, VISTA, KIR, NKG2A, B7-H3/H4. The Report has also emphasized on the Oncolytic viruses, Neo-Antigen therapies, TCR Therapies and CAR-T therapies.

Some of the key players operating in global immuno-oncology market are Bristol Myers Squibb, Merck, AstraZeneca, Roche Holding AG, Pfizer Inc., and Incyte Corporation among others.

Request For Discount: https://www.polarismarketresearch.com/industry-analysis/immuno-oncology-io-market/request-for-discount-pricing

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world

Contact us

Polaris Market Research

Phone: 1-646-568-9980

Email: sales@polarismarketresearch.com

Web: www.polarismarketresearch.com

[databridgemarket456]

The immuno-oncology (IO) market is expected to witness market growth at a rate of 8.90% in the forecast period of 2022 to 2029. Data Bridge Market Research report on the immuno-oncology (IO) market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. 

[udaycmi]

Immuno Oncology Market 2021 Future Growth Analysis and Challenges

The global immuno-oncology market size is expected to reach USD 38.89 billion by 2025 according to a new study by Polaris Market Research. The report “Immuno Oncology (I-O) Market Size, Trends, Industry Analysis By Treatment Approaches (Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, and Cytokines); By Novel Targets (IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, and A2AR antagonist/CD73i); By Tumor Types; By Region: Market Size & Forecast, 2020 – 2026” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Immuno-oncology, also called as cancer immunotherapy is a biologic treatment, which enhances the body’s natural defenses to stop the growth of cancer. This therapy uses constituents made by the body or in a research laboratory to improve or reestablish the immune system function.

Get Sample copy of this report: https://www.polarismarketresearch.com/industry-analysis/immuno-oncology-io-market/request-for-sample

Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. Currently, world is at the forefront of this science with several compounds in development that are being investigated for use in a variety of cancers, as well as an approved immuno-oncology medicine that continues to be studied for new uses. The more precise targeting of patients for selected therapies is another important area of focus in oncology. Clinical biomarkers and pharmacogenomic studies are increasingly used to identify groups and sub-groups of patients most likely to benefit from an investigational agent in order to maximize its potential benefits.

The global immuno-oncology market is driven by the factors such as rising occurrence of different forms of cancer, technological advancements in the field of immune oncology for cancer treatment, and rising awareness concerning the benefits of ablation procedures over conventional treatment procedures. Moreover, rising number of ablation centers, surgical centers, and hospitals are driving the growth of tumor ablation market globally. Additionally, the developments in oncology treatments, leading to the increased development of pioneering products are also advancing towards significant growth of the global Immune Oncology market.

The increasing trend was also seen in the research in the novel agents and increase in the number of clinical trials in combinations as well as monotherapy. The most notable new agents in Immuno-Oncology are IDO’s, LAG-3, TIGIT, TIM-3, VISTA, KIR, NKG2A, B7-H3/H4. The Report has also emphasized on the Oncolytic viruses, Neo-Antigen therapies, TCR Therapies and CAR-T therapies.

Some of the key players operating in global immuno-oncology market are Bristol Myers Squibb, Merck, AstraZeneca, Roche Holding AG, Pfizer Inc., and Incyte Corporation among others.

Request For Discount: https://www.polarismarketresearch.com/industry-analysis/immuno-oncology-io-market/request-for-discount-pricing

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world

Contact us

Polaris Market Research

Phone: 1-646-568-9980

Email: sales@polarismarketresearch.com

Web: www.polarismarketresearch.com

[karishmamulani]

Immuno Oncology (I-O) Market Evolving Opportunities, Covid-19 Impact, Strategies And Forecast

The report “Immuno Oncology (I-O) Market Size, Trends, Industry Analysis By Treatment Approaches (Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, and Cytokines); By Novel Targets (IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, and A2AR antagonist/CD73i); By Tumor Types; By Region: Market Size & Forecast, 2020 – 2026” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The global immuno-oncology market size is expected to reach USD 38.89 billion by 2025 according to a new study by Polaris Market Research. Immuno-oncology, also called as cancer immunotherapy is a biologic treatment, which enhances the body’s natural defenses to stop the growth of cancer. This therapy uses constituents made by the body or in a research laboratory to improve or reestablish the immune system function.

Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. Currently, world is at the forefront of this science with several compounds in development that are being investigated for use in a variety of cancers, as well as an approved immuno-oncology medicine that continues to be studied for new uses. The more precise targeting of patients for selected therapies is another important area of focus in oncology. Clinical biomarkers and pharmacogenomic studies are increasingly used to identify groups and sub-groups of patients most likely to benefit from an investigational agent in order to maximize its potential benefits.

Get Sample PDF @ https://www.polarismarketresearch.com/industry-analysis/immuno-oncology-io-market/request-for-sample

Some of the key players operating in global immuno-oncology market are Bristol Myers Squibb, Merck, AstraZeneca, Roche Holding AG, Pfizer Inc., and Incyte Corporation among others.

The global immuno-oncology market is driven by the factors such as rising occurrence of different forms of cancer, technological advancements in the field of immune oncology for cancer treatment, and rising awareness concerning the benefits of ablation procedures over conventional treatment procedures. Moreover, rising number of ablation centers, surgical centers, and hospitals are driving the growth of tumor ablation market globally. Additionally, the developments in oncology treatments, leading to the increased development of pioneering products are also advancing towards significant growth of the global Immune Oncology market.

The increasing trend was also seen in the research in the novel agents and increase in the number of clinical trials in combinations as well as monotherapy. The most notable new agents in Immuno-Oncology are IDO’s, LAG-3, TIGIT, TIM-3, VISTA, KIR, NKG2A, B7-H3/H4. The Report has also emphasized on the Oncolytic viruses, Neo-Antigen therapies, TCR Therapies and CAR-T therapies.

Get Special Discount On this Research Report @ https://www.polarismarketresearch.com/industry-analysis/immuno-oncology-io-market/request-for-discount-pricing

On the basis of treatment type, the global immuno-oncology market is segmented into Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, and Cytokines. Checkpoint inhibitors were the largest treatment process segment in 2019 that accounted for 55.2% of the overall revenue. On the basis of novel targets, the global market is segmented into IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, and A2AR antagonist/CD73i. VEGFi was the largest novel target segment that was used for immuno-oncology treatment processes in 2019 with a total market share of 11.2%. on the basis of cancer type, the global immuno-oncology Market is segmented into Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Head, face & Neck Cancer, Bladder Cancer, Classical Hodgkin’s Lymphoma, Merkel Cell, and carcinoma. Revenue share of immuno-oncology treatment for classical hodgkin’s lymphoma was the largest in 2019 i.e. 15.31% among the listed tumor types in the report.

On the basis of geography, North America was the largest regional market in 2019. High levels of spending on cancer treatments, also U.S. being one of the major country y with a huge population of cancer affected people on a global scale, the country being the host to the development of this technology, higher frequency of innovations of immuno oncology treatments or processes in the region specially in the U.S. etc., all of these factors have driven significant investment and alongside the demand for IO in the region. These factors have driven the North American market since the inception of this technology and over the forecast period it is expected to increase further.

Buy Now : https://www.polarismarketresearch.com/checkouts/751

[sandlerresearch]

Immuno-Oncology - Market Analysis, Trends, Opportunities and Unmet Needs - Thematic Research published on

https://www.sandlerresearch.org/immuno-oncology-market-analysis-trends-opportunities-and-unmet-needs-thematic-research.html

Immuno-Oncology - Market Analysis, Trends, Opportunities and Unmet Needs - Thematic Research

Immuno-Oncology – Market Analysis, Trends, Opportunities and Unmet Needs – Thematic Research

Summary

Immuno-oncology (IO) describes the treatment of various cancers with the use of bispecific-antibodies, cancer vaccines, cell therapies, checkpoint modulators and oncolytic viruses. These classes of IO therapies achieved sales of ~$30B in 2019, which is projected to reach ~$95B by 2026. Of these, checkpoint modulators is the most valuable segment, forecast to achieve $66B in sales by 2026.

The field of (IO) is consolidating its presence in most major types of cancer, as there are now 22 marketed agents in the 7MM (United States, France, Germany, Italy, Spain, United Kingdom, and Japan), the majority being cancer vaccines, followed by 8 checkpoint modulators and 4 cell therapies.

IO agents are part of the standard of care in major cancer types, such as Melanoma, Lung, and Head & Neck Cancer. The clinical activity in the field is among the highest in oncology, with 4,822 clinical trials in the 7MM as of December 2020 and 422 drugs in clinical development.

The report “Immuno-Oncology – Market Analysis, Trends, Opportunities and Unmet Needs” assesses physician perceptions on use of immuno-oncology drugs in clinical practice in the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan. It also provides the landscape of marketed and pipeline immuno-oncology drugs across the five major classes (bispecific antibodies, cancer vaccines, cell therapies, checkpoint modulators and oncolytic viruses), opportunities, challenges, and unmet needs.

There is also a market analysis section with forecasts, as well as information on regulation and market access. The report combines information obtained from secondary sources and primary research with specialists and physicians from different disease areas within oncology who utilize immuno-oncology drug approaches during treatment.

Components of the report include primary and secondary research –

– Quotes from key opinion leaders and payers – Summary of immuno-oncology definitions and classifications – Overview of key marketed and pipeline immuno-oncology drugs, including bispecific antibodies, cancer vaccines, cell therapies, checkpoint modulators and oncolytic viruses – Trends in the immuno-oncology drug market – Call-outs of key information and details – Insight from GlobalData’s specialist healthcare analysts

Key Questions Answered –

– What impact will late-stage pipeline agents have on the market? Which class of IO drugs will have the highest peak sales, and why? – What are the current unmet needs in IO, which pipeline agents or strategies are positioned to counter these unmet needs? What are the opportunities for R&D? – How is the field of checkpoint modulation going to move forward? Which technologies are the most promising for combinations? – What is the regulatory landscape for IO agents in the US, the 5EU and Japan? – What is the current and future outlook of IO according to high prescribers?

Key findings from the report include –

– The field of immuno-oncology (IO) is consolidating its presence in most major types of cancer: There are currently 22 marketed IO products in the 7MM. Prophylactic and therapeutic cancer vaccines lead the category with 9 products, followed by checkpoint modulators with 8 approved drugs and cell therapies with 4 approved drugs. As of December 2020, there are 4,822 clinical trials investigating IO across the 7MM with 422 drugs in development. – Checkpoint modulation is the most valuable IO sector: The checkpoint modulation market was valued at $24B in 2019 globally and is forecast to reach $66.5B by 2026, with Merck’s Keytruda (pembrolizumab) leading the market. Key patent expiries for checkpoint modulators in the decade 2020-2030 will start eroding market value away from branded agents and into biosimilars. – Existing programs facilitate the approval and development of IO: Special new designations for certain components of IO can be assigned such as RMAT in the US and ATMP in the EU. Countries in the 7MM have set programs to expedite IO therapy approvals, especially when they address an unmet need or are targeting orphan indications. – High cost of therapy and need for personalized treatment using biomarkers remain as unmet needs: Despite new competitors entering the market, IO agents have retained or increased their very high prices, causing concern for their future use in most markets The need for better biomarkers to guide treatment decisions is well-documented and new efforts in the industry may move the needle in the next five years.

Scope

– Overview of immuno-oncology including classification of therapy and technologies, regulatory and market access details, product & company profiles. – Quotes from US- and 5EU-based key opinion leaders and payers. – Key topics covered for IO in the 7MM include trends, value chain, market analysis, opportunities, challenges and unmet needs and high-value deals. – Pipeline analysis: Comprehensive data split across different phases and indications, emerging novel trends under development, and analysis of the most promising late-stage pipeline drugs for each class of IO (Phase II – III). – Analysis of the key dynamics of the IO market. Insightful review of the key industry drivers and challenges. Deals and R&D strategies covered in detail to highlight business opportunities. – Robust analysis of high-prescriber survey conducted with 80 oncologists.

Reasons to Buy

The report will enable you to – – Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current deals and technologies to identify companies with the highest potential. – Develop business strategies by understanding the trends shaping and driving the global immuno-oncology therapeutics market. – Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global immuno-oncology market in the future. – Design your development strategy through a review of potential novel targets or combinations across indications. – Understand the challenges and strategies impacting the development of immuno-oncology agents in preclinical studies and clinical trials. – Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. – Organize your sales and marketing efforts by identifying the classes of IO and indications that present maximum opportunities for consolidations, investments and strategic partnerships.